Want to see IN:MARKSANS full AI Analyst Report?
Total Valuation
Marksans Pharma Limited has a market cap or net worth of ₹145.58B. The enterprise value is ₹65.05K.
Market Cap₹145.58B
Enterprise Value₹65.05K
Share Statistics
Marksans Pharma Limited has 453,163,760 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding453,163,760
Owned by Insiders―
Owned by Institutions0.13%
Financial Efficiency
Marksans Pharma Limited’s return on equity (ROE) is 0.14 and return on invested capital (ROIC) is 11.10%.
Return on Equity (ROE)0.14
Return on Assets (ROA)0.11
Return on Invested Capital (ROIC)11.10%
Return on Capital Employed (ROCE)0.15
Revenue Per Employee17.51M
Profits Per Employee2.48M
Employee Count1,685
Asset Turnover0.76
Inventory Turnover1.85
Valuation Ratios
The current PE Ratio of Marksans Pharma Limited is 28.2. Marksans Pharma Limited’s PEG ratio is 1.74.
PE Ratio28.2
PS Ratio2.41
PB Ratio2.35
Price to Fair Value2.35
Price to FCF20.26
Price to Operating Cash Flow193.66
PEG Ratio1.74
Income Statement
In the last 12 months, Marksans Pharma Limited had revenue of 29.51B and earned 4.18B in profits. Earnings per share was 9.22.
Revenue29.51B
Gross Profit11.57B
Operating Income5.05B
Pretax Income5.61B
Net Income4.18B
EBITDA6.03B
Earnings Per Share (EPS)9.22
Cash Flow
In the last 12 months, operating cash flow was 751.86M and capital expenditures -731.89M, giving a free cash flow of 19.97M billion.
Operating Cash Flow751.86M
Free Cash Flow19.97M
Free Cash Flow per Share0.04
Dividends & Yields
Marksans Pharma Limited pays an annual dividend of ₹0.9, resulting in a dividend yield of 0.28%
Dividend Per Share₹0.9
Dividend Yield0.28%
Payout Ratio10.06%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.30
52-Week Price Change81.18%
50-Day Moving Average271.72
200-Day Moving Average207.91
Relative Strength Index (RSI)68.06
Average Volume (3m)99.03K
Important Dates
Marksans Pharma Limited upcoming earnings date is Nov 18, 2026, TBA (Confirmed).
Last Earnings DateAug 12, 2026
Next Earnings DateNov 18, 2026
Ex-Dividend Date―
Financial Position
Marksans Pharma Limited as a current ratio of 5.17, with Debt / Equity ratio of 0.00%
Current Ratio5.17
Quick Ratio3.32
Debt to Market Cap<0.01
Net Debt to EBITDA-0.48
Interest Coverage Ratio20.92
Taxes
In the past 12 months, Marksans Pharma Limited has paid 1.40B in taxes.
Income Tax1.40B
Effective Tax Rate0.25
Enterprise Valuation
Marksans Pharma Limited EV to EBITDA ratio is 11.30, with an EV/FCF ratio of 19.43.
EV to Sales2.31
EV to EBITDA11.30
EV to Free Cash Flow19.43
EV to Operating Cash Flow14.16
Balance Sheet
Marksans Pharma Limited has ₹9.91B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of ₹9.91B billion.
Cash & Marketable Securities₹9.91B
Total Debt₹0.00
Net Cash₹9.91B
Net Cash Per Share₹21.87
Tangible Book Value Per Share₹63.78
Margins
Gross margin is 44.34%, with operating margin of 17.10%, and net profit margin of 14.16%.
Gross Margin44.34%
Operating Margin17.10%
Pretax Margin19.00%
Net Profit Margin14.16%
EBITDA Margin20.45%
EBIT Margin17.10%
Analyst Forecast
The average price target for Marksans Pharma Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast19.59%
EPS Growth Forecast47.58%